宫颈癌仍然是全世界最常见的妇科恶性肿瘤之一。由于筛查和治疗不足，发展中国家的病例负担过重。即使在接受充分治疗的患者中，如果存在局部晚期或复发性疾病，结果往往很差。将生物疗法引入治疗中提高了总体生存率；然而，仍然存在很大的机会来提高目前的治疗标准。生物制剂已在多种肿瘤类型中显示出抗肿瘤活性，并正在积极寻求用于宫颈癌的治疗。在本文中，我们将讨论宫颈癌生物制剂治疗的历史演变，包括使用血管生成抑制剂、免疫检查点抑制剂、抗体药物缀合物和疫苗。我们将回顾如何将这些疗法纳入当前的治疗建议，并讨论正在进行的旨在改善临床结果的研究。我们还假设护理方面存在持续的差距。生物疗法对我们当前治疗宫颈癌的方法产生了巨大影响。我们预计，更多的研究和开发将致力于宫颈癌生物制剂的持续研究，以努力改善这种历史上难以治疗的恶性肿瘤。

Cervical cancer remains one of the most common gynecologic malignancies worldwide. A disproportionate burden of cases occurs in developing countries due to inadequate screening and treatment. Even among patients adequately treated, in the presence of locally advanced or recurrent disease, outcomes tend to be poor. The introduction of biologic therapy into treatment has increased overall survival; however, a considerable opportunity still exists to improve current standards in treatment. Biologics have shown antitumor activity in multiple tumor types and are actively being pursued for the management of cervical cancer.In this article, we will discuss the historical evolution of biologic therapy in cervical cancer including use of angiogenesis inhibitors, immune checkpoint inhibitors, antibody-drug conjugates, and vaccines. We will review how these therapies have been integrated into current treatment recommendations and discuss ongoing investigations intended to improve clinical outcomes. We also postulate on persistent gaps in care.Biologic therapies have had a tremendous impact on our current approach to managing cervical cancer. We anticipate that significant more research and development will be committed to the continued investigation of biologics in cervical cancer in an effort to improve a historically difficult to treat malignancy.